Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

被引：54

作者：

Joerger, Markus

Cassier, Philippe Alexandre

Penel, Nicolas

Cathomas, Richard

Richly, Heike

Schostak, Martin

Janitzky, Andreas

Wermke, Martin

Nogova, Lucia

Tai, David Wai-Meng

Sayehli, Cyrus

Grullich, Carsten

Grande, Enrique

Navarro, Alejandro

Park, Se Hoon

Nogai, Hendrik

Bender, Sebastian

Ellinghaus, Peter

Schuler, Martin H.

机构：

[1] Cantonal Hosp St Gallen, St Gallen, Switzerland

[2] Ctr Leon Berard, Lyon, France

[3] Oscar Lambret Canc Ctr, Lille, France

[4] Kantonsspital, Chur, Switzerland

[5] Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany

[6] Univ Magdeburg, Magdeburg, Germany

[7] Otto von Guericke Univ, Magdeburg, Germany

[8] Techn Univ Dresden, Carl Gustav Carus Dresden, Dresden, Germany

[9] Univ Hosp Cologne, Lung Canc Grp Cologne, Ctr Integrated Oncol, Cologne, Germany

[10] Natl Canc Ctr Singapore, Singapore, Singapore

[11] Univ Klin Wurzburg, Wurzburg, Germany

[12] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[13] MD Anderson Canc Ctr, Madrid, Spain

[14] Vall Hebron Univ Hosp, Barcelona, Spain

[15] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[16] Bayer AG, Div Pharmaceut, Berlin, Germany

[17] Bayer AG, Div Pharmaceut, Wuppertal, Germany

[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

4513

引用

页数：2